Nokes D James, Abwao John, Pamba Allan, Peenze Ina, Dewar John, Maghenda J Kamino, Gatakaa Hellen, Bauni Evasius, Scott J Anthony G, Maitland Kathryn, Williams Thomas N
Kenya Medical Research Institute, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
PLoS Med. 2008 Jul 22;5(7):e153. doi: 10.1371/journal.pmed.0050153.
Rotavirus, predominantly of group A, is a major cause of severe diarrhoea worldwide, with the greatest burden falling on young children living in less-developed countries. Vaccines directed against this virus have shown promise in recent trials, and are undergoing effectiveness evaluation in sub-Saharan Africa. In this region limited childhood data are available on the incidence and clinical characteristics of severe group A rotavirus disease. Advocacy for vaccine intervention and interpretation of effectiveness following implementation will benefit from accurate base-line estimates of the incidence and severity of rotavirus paediatric admissions in relevant populations. The study objective was to accurately define the incidence and severity of group A rotavirus disease in a resource-poor setting necessary to make informed decisions on the need for vaccine prevention.
Between 2002 and 2004 we conducted prospective surveillance for group A rotavirus infection at Kilifi District Hospital in coastal Kenya. Children < 13 y of age were eligible as "cases" if admitted with diarrhoea, and "controls" if admitted without diarrhoea. We calculated the incidence of hospital admission with group A rotavirus using data from a demographic surveillance study of 220,000 people in Kilifi District. Of 15,347 childhood admissions 3,296 (22%) had diarrhoea, 2,039 were tested for group A rotavirus antigen and, of these, 588 (29%) were positive. 372 (63%) rotavirus-positive cases were infants. Of 620 controls 19 (3.1%, 95% confidence interval [CI] 1.9-4.7) were rotavirus positive. The annual incidence (per 100,000 children) of rotavirus-positive admissions was 1,431 (95% CI 1,275-1,600) in infants and 478 (437-521) in under-5-y-olds, and highest proximal to the hospital. Compared to children with rotavirus-negative diarrhoea, rotavirus-positive cases were less likely to have coexisting illnesses and more likely to have acidosis (46% versus 17%) and severe electrolyte imbalance except hyponatraemia. In-hospital case fatality was 2% among rotavirus-positive and 9% among rotavirus-negative children.
In Kilifi > 2% of children are admitted to hospital with group A rotavirus diarrhoea in the first 5 y of life. This translates into over 28,000 vaccine-preventable hospitalisations per year across Kenya, and is likely to be a considerable underestimate. Group A rotavirus diarrhoea is associated with acute life-threatening metabolic derangement in otherwise healthy children. Although mortality is low in this clinical research setting this may not be generally true in African hospitals lacking rapid and appropriate management.
轮状病毒,主要是A组轮状病毒,是全球严重腹泻的主要病因,对生活在欠发达国家的幼儿影响最大。针对这种病毒的疫苗在近期试验中显示出前景,目前正在撒哈拉以南非洲进行有效性评估。在该地区,关于A组严重轮状病毒疾病的发病率和临床特征的儿童数据有限。倡导疫苗干预以及实施后对有效性的解读将受益于对相关人群中轮状病毒儿科住院发病率和严重程度的准确基线估计。研究目的是在资源匮乏地区准确界定A组轮状病毒疾病的发病率和严重程度,以便就是否需要疫苗预防做出明智决策。
2002年至2004年期间,我们在肯尼亚沿海的基利菲区医院对A组轮状病毒感染进行了前瞻性监测。年龄<13岁的儿童,因腹泻入院者作为“病例”,无腹泻入院者作为“对照”。我们利用基利菲区22万人的人口监测研究数据计算A组轮状病毒住院发病率。在15347例儿童住院病例中,3296例(22%)有腹泻症状,其中2039例接受了A组轮状病毒抗原检测,其中588例(29%)呈阳性。372例(63%)轮状病毒阳性病例为婴儿。在620例对照中,19例(3.1%,95%置信区间[CI]1.9 - 4.7)轮状病毒呈阳性。轮状病毒阳性住院病例的年发病率(每10万名儿童)在婴儿中为1431例(95%CI 1275 - 1600),在5岁以下儿童中为478例(437 - 521),且在医院附近发病率最高。与轮状病毒阴性腹泻儿童相比,轮状病毒阳性病例合并其他疾病的可能性较小,更易发生酸中毒(46%对17%)以及除低钠血症外的严重电解质失衡。轮状病毒阳性儿童的院内病死率为2%,轮状病毒阴性儿童为9%。
在基利菲,超过2%的儿童在生命的前5年因A组轮状病毒腹泻入院。这意味着肯尼亚每年有超过28000例可通过疫苗预防的住院病例,而且这很可能是一个严重低估的数字。A组轮状病毒腹泻与原本健康的儿童出现危及生命的急性代谢紊乱有关。尽管在本临床研究环境中死亡率较低,但在缺乏快速和适当管理的非洲医院可能并非普遍如此。